Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
354,20 €
+0,70 €
+0,20%
09:07:48 Uhr
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,93%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-

Roche Holding News

01.08.25 - GlobeNewswire
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two ...
28.07.25 - GlobeNewswire
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E ...
25.07.25 - GlobeNewswire
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) ...
24.07.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
Basel, 24 July 2025
24.07.25 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starkes Wachstum im ersten Halbjahr 2025 fort: Verkäufe steigen um 7% (CER)
Basel, 24. Juli 2025
23.07.25 - GlobeNewswire
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology. The minimally invasive, blood-​based test can ...
23.07.25 - GlobeNewswire
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-​free survival compared with palbociclib and fulvestrant alone 1 ...
22.07.25 - GlobeNewswire
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-​voting equity securities (Genussscheine). Reduction of the nominal ...
22.07.25 - GlobeNewswire
Roche Verwaltungsrat schlägt Umtausch von Genussscheinen in Partizipationsscheine vor
Partizipationsscheine mit einem Nennwert von je CHF 0.001 ersetzen die Genussscheine. Herabsetzung des Nennwerts der Inhaberaktien von CHF 1.00 auf CHF 0.001 je Aktie, zur ...
21.07.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was ...
07.07.25 - PR Newswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs PR Newswire
30.06.25 - GlobeNewswire
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early ...
23.06.25 - GlobeNewswire
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the ...
20.06.25 - GlobeNewswire
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-​free survival - three times longer than R-GemOx 1 This well-​tolerated investigational combination ...
16.06.25 - GlobeNewswire
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-​stage Parkinson’s disease Prasinezumab is a ...
15.06.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-​risk for the use of Elevidys in non-​ambulatory patients with Duchenne has been re-​assessed, following two cases of fatal acute liver ...
04.06.25 - GlobeNewswire
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety ...
03.06.25 - GlobeNewswire
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First ...
31.05.25 - GlobeNewswire
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The Itovebi TM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA -mutated HR-​positive, HER2-negative advanced breast cancer, ...
30.05.25 - GlobeNewswire
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib ...

Newssuche

Videos

newspaper
16.04.26 +0,05%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »